tiprankstipranks

Prime Medicine started with Outperform on ‘differentiated’ platform at Wedbush

Wedbush analyst David Nierengarten last night initiated coverage of Prime Medicine with an Outperform rating and $12 price target. The shares shares are undervalued based on a positive long-term outlook on the company’s “differentiated and versatile” gene editing platform, prime editing, the analyst tells investors in a research note. The firm says prime editing is capable of repairing 90% of known genetic mutations. It believes prime editing could be the go-to technology to treat or cure a significant number of genetic diseases.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue